Outset Medical, Inc. is a medical technology firm that specializes in developing hemodialysis systems. The company's primary product is the Tablo Hemodialysis System, a compact console designed to deliver dialysis treatment in various environments, including hospitals and patients' homes. This innovative system boasts…
An institutional-grade, numbers-driven thesis on OM — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 16, 2026, TradersQuant's model rates Outset Medical, Inc. (OM) 61/100 with a 12-month base-case forecast of $14.00 — +210.4% versus the current price of $4.51. Outset Medical, Inc. trades at $4.51 in the Healthcare sector, with a market capitalisation of $83.6M. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for OM is $14.00, implying +210.4% versus the current price. The model's 12-month scenario range runs from $1.93 (bear) to $5.01 (bull), with a base case of $3.16.
On the fundamentals, Outset Medical shows a P/E of -1.1, trailing revenue of $119.5M, revenue growth of +5.1% YoY. This page also tracks OM's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
OM currently carries a TradersQuant composite score of 61/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $14.00 implies +210.4% from $4.51. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for OM is $14.00, about +210.4% versus the latest price of $4.51. Consensus is based on 11 analysts.
TradersQuant's 12-month model forecast for OM is a base case of $3.16, ranging from $1.93 (bear) to $5.01 (bull), an expected return of -29.9%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for OM over the next 12 months is $3.16 in the base case (bear $1.93, bull $5.01), versus today's price of $4.51. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for OM — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates OM's fair value at $14.00, implying +210.4% of expected upside versus the current price.
Outset Medical does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
